Bone disease in primary biliary cirrhosis

Does ursodeoxycholic acid make a difference?

Keith Lindor, Christine H. Janes, Jeffrey S. Crippin, Roberta A. Jorgensen, E. Rolland Dickson

Research output: Contribution to journalArticle

101 Citations (Scopus)

Abstract

Ursodeoxycholic acid (UDCA) has been proposed as beneficial therapy for patients with primary biliary cirrhosis (PBC). The effects of UDCA on metabolic bone disease, a major source of morbidity in patients with PBC, are essentially unknown. Preliminary information suggests that UDCA may improve biochemical indices of bone disease, although information about the effects of UDCA on bone density is lacking. In this study, we describe the effects of UDCA on lumbar spine bone mineral densities over a 3-year period during which patients were enrolled in a randomized, double-blind, therapeutic trial of UDCA for the treatment of PBC. Lumbar spine dual-photon densitometry was measured at entry and annually. Eighty-eight patients, 50 in the UDCA group and 38 in the placebo group, had serial measurements available for up to 3 years. There was no statistical difference between the two treatment groups at entry with respect to histological stage, total bilirubin, age, use of calcium supplement, vitamin D levels, or estrogen. After 3 years of treatment, there was no significant difference in the lumbar spine bone densitometry measurements between the UDCA-treated and placebo groups. We conclude that, after 3 years of treatment, UDCA is not associated with statistically significant differences in the rate of bone loss from the lumbar spine in patients when compared with placebo despite beneficial effects of treatment on the underlying liver disease. Further efforts to define effective treatments for the bone disease need to be pursued.

Original languageEnglish (US)
Pages (from-to)389-392
Number of pages4
JournalHepatology
Volume21
Issue number2
DOIs
StatePublished - 1995
Externally publishedYes

Fingerprint

Ursodeoxycholic Acid
Biliary Liver Cirrhosis
Bone Diseases
Spine
Densitometry
Placebos
Therapeutics
Bone Density
Bone and Bones
Metabolic Bone Diseases
Photons
Bilirubin
Vitamin D
Liver Diseases
Estrogens
Calcium
Morbidity

ASJC Scopus subject areas

  • Hepatology

Cite this

Bone disease in primary biliary cirrhosis : Does ursodeoxycholic acid make a difference? / Lindor, Keith; Janes, Christine H.; Crippin, Jeffrey S.; Jorgensen, Roberta A.; Dickson, E. Rolland.

In: Hepatology, Vol. 21, No. 2, 1995, p. 389-392.

Research output: Contribution to journalArticle

Lindor, Keith ; Janes, Christine H. ; Crippin, Jeffrey S. ; Jorgensen, Roberta A. ; Dickson, E. Rolland. / Bone disease in primary biliary cirrhosis : Does ursodeoxycholic acid make a difference?. In: Hepatology. 1995 ; Vol. 21, No. 2. pp. 389-392.
@article{91b04f3d9d804db281bf91fad5c18181,
title = "Bone disease in primary biliary cirrhosis: Does ursodeoxycholic acid make a difference?",
abstract = "Ursodeoxycholic acid (UDCA) has been proposed as beneficial therapy for patients with primary biliary cirrhosis (PBC). The effects of UDCA on metabolic bone disease, a major source of morbidity in patients with PBC, are essentially unknown. Preliminary information suggests that UDCA may improve biochemical indices of bone disease, although information about the effects of UDCA on bone density is lacking. In this study, we describe the effects of UDCA on lumbar spine bone mineral densities over a 3-year period during which patients were enrolled in a randomized, double-blind, therapeutic trial of UDCA for the treatment of PBC. Lumbar spine dual-photon densitometry was measured at entry and annually. Eighty-eight patients, 50 in the UDCA group and 38 in the placebo group, had serial measurements available for up to 3 years. There was no statistical difference between the two treatment groups at entry with respect to histological stage, total bilirubin, age, use of calcium supplement, vitamin D levels, or estrogen. After 3 years of treatment, there was no significant difference in the lumbar spine bone densitometry measurements between the UDCA-treated and placebo groups. We conclude that, after 3 years of treatment, UDCA is not associated with statistically significant differences in the rate of bone loss from the lumbar spine in patients when compared with placebo despite beneficial effects of treatment on the underlying liver disease. Further efforts to define effective treatments for the bone disease need to be pursued.",
author = "Keith Lindor and Janes, {Christine H.} and Crippin, {Jeffrey S.} and Jorgensen, {Roberta A.} and Dickson, {E. Rolland}",
year = "1995",
doi = "10.1016/0270-9139(95)90097-7",
language = "English (US)",
volume = "21",
pages = "389--392",
journal = "Hepatology",
issn = "0270-9139",
publisher = "John Wiley and Sons Ltd",
number = "2",

}

TY - JOUR

T1 - Bone disease in primary biliary cirrhosis

T2 - Does ursodeoxycholic acid make a difference?

AU - Lindor, Keith

AU - Janes, Christine H.

AU - Crippin, Jeffrey S.

AU - Jorgensen, Roberta A.

AU - Dickson, E. Rolland

PY - 1995

Y1 - 1995

N2 - Ursodeoxycholic acid (UDCA) has been proposed as beneficial therapy for patients with primary biliary cirrhosis (PBC). The effects of UDCA on metabolic bone disease, a major source of morbidity in patients with PBC, are essentially unknown. Preliminary information suggests that UDCA may improve biochemical indices of bone disease, although information about the effects of UDCA on bone density is lacking. In this study, we describe the effects of UDCA on lumbar spine bone mineral densities over a 3-year period during which patients were enrolled in a randomized, double-blind, therapeutic trial of UDCA for the treatment of PBC. Lumbar spine dual-photon densitometry was measured at entry and annually. Eighty-eight patients, 50 in the UDCA group and 38 in the placebo group, had serial measurements available for up to 3 years. There was no statistical difference between the two treatment groups at entry with respect to histological stage, total bilirubin, age, use of calcium supplement, vitamin D levels, or estrogen. After 3 years of treatment, there was no significant difference in the lumbar spine bone densitometry measurements between the UDCA-treated and placebo groups. We conclude that, after 3 years of treatment, UDCA is not associated with statistically significant differences in the rate of bone loss from the lumbar spine in patients when compared with placebo despite beneficial effects of treatment on the underlying liver disease. Further efforts to define effective treatments for the bone disease need to be pursued.

AB - Ursodeoxycholic acid (UDCA) has been proposed as beneficial therapy for patients with primary biliary cirrhosis (PBC). The effects of UDCA on metabolic bone disease, a major source of morbidity in patients with PBC, are essentially unknown. Preliminary information suggests that UDCA may improve biochemical indices of bone disease, although information about the effects of UDCA on bone density is lacking. In this study, we describe the effects of UDCA on lumbar spine bone mineral densities over a 3-year period during which patients were enrolled in a randomized, double-blind, therapeutic trial of UDCA for the treatment of PBC. Lumbar spine dual-photon densitometry was measured at entry and annually. Eighty-eight patients, 50 in the UDCA group and 38 in the placebo group, had serial measurements available for up to 3 years. There was no statistical difference between the two treatment groups at entry with respect to histological stage, total bilirubin, age, use of calcium supplement, vitamin D levels, or estrogen. After 3 years of treatment, there was no significant difference in the lumbar spine bone densitometry measurements between the UDCA-treated and placebo groups. We conclude that, after 3 years of treatment, UDCA is not associated with statistically significant differences in the rate of bone loss from the lumbar spine in patients when compared with placebo despite beneficial effects of treatment on the underlying liver disease. Further efforts to define effective treatments for the bone disease need to be pursued.

UR - http://www.scopus.com/inward/record.url?scp=0028911341&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028911341&partnerID=8YFLogxK

U2 - 10.1016/0270-9139(95)90097-7

DO - 10.1016/0270-9139(95)90097-7

M3 - Article

VL - 21

SP - 389

EP - 392

JO - Hepatology

JF - Hepatology

SN - 0270-9139

IS - 2

ER -